Holen Sie sich die Stockscreener-App
0.5626
2.00%
-0.0153
Schlusskurs vom Vortag:
$0.5779
Offen:
$0.5991
24-Stunden-Volumen:
18,351
Relative Volume:
0.03
Marktkapitalisierung:
$7.21M
Einnahmen:
$1.85M
Nettoeinkommen (Verlust:
$-5.56M
KGV:
-0.7419
EPS:
-0.7583
Netto-Cashflow:
-
1W Leistung:
-10.16%
1M Leistung:
+24.43%
6M Leistung:
-80.06%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.5645
$0.5991
1-Wochen-Bereich:
$0.5664
$0.6212
52-Wochen-Spanne:
$0.4011
$14.09
20 20 Biolabs Inc Stock (AIDX) Company Profile
Firmenname
20 20 Biolabs Inc
Sektor
Branche
Telefon
(240) 453-6339
Adresse
9430 KEY WEST AVENUE, ROCKVILLE
Compare AIDX vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AIDX
20 20 Biolabs Inc
|
0.5645 | 7.38M | 1.85M | -5.56M | 0 | -0.7583 |
ABT
Abbott Laboratories
|
105.79 | 182.59B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.36 | 118.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
272.51 | 106.03B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.17 | 65.19B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.17 | 49.99B | 6.30B | 1.07B | 1.09B | 1.8406 |
20 20 Biolabs Inc Aktie (AIDX) Neueste Nachrichten
20/20 Biolabs outlines FDA engagement, Medicare reimbursement pathway and commercial gains - TradingView
20/20 BioLabs says its cancer blood test hit record quarterly revenue - Stock Titan
20/20 Biolabs (AIDX) Holds Above $0.60 Support After Modest GainDefined Outcome ETF - dars.gov.et
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity - Barchart.com
20/20 BioLabs to Discuss Record Q2 OneTest Revenue, Next Generation Dx Summit Takeaways and Commercial Strategy at September 2 Webinar - quiverquant.com
20/20 BioLabs reschedules investor webinar to 2 pm ET on Sept 2 - scanx.trade
20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity - finance.yahoo.com
AIDX | 20/20 Biolabs, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
20/20 Biolabs, Inc. Common Stock (NASDAQ: AIDX) Stock Price, News & Analysis - kalkine.ca
Form 8K 20/20 BIOLABS For: 19 August By Investing.com - Investing.com Nigeria
20/20 Biolabs adjourns vote on charter amendment, elects directors at annual meeting - Investing.com
20/20 (AIDX) Update: Records a 1.45% Decrease to $0.51 at the Close; Price Context: the Near-Term Reference Band Stretches From $0.48 to $0.54 at the CloseMcClellan Oscillator - vinanet.vn
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level - Sahm
20/20 Biolabs Releases Q2 2026 Financial Results - AlphaStreet
20/20 Biolabs Q2 Results: EPS misses, revenue up 36% - scanx.trade
20/20 Biolabs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
20/20 Biolabs to host investor webinar; reports best quarterly cancer-test revenue to date - tradingview.com
After Taipei, Tokyo and Seoul, 20/20 BioLabs to discuss deal options - Stock Titan
20/20 BioLabs sets Aug 5 webinar on East Asia roll-up strategy - scanx.trade
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy - The Manila Times
20/20 BioLabs meets potential partners in East Asia - Investing.com
20/20 BioLabs meets potential partners in East Asia By Investing.com - Investing.com Canada
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets - GlobeNewswire
20/20 BioLabs seeks East Asia M&A, JV deals to roll up AI blood test assets - scanx.trade
20/20 Biolabs, Inc. Revenue Breakdown – NASDAQ:AIDX - TradingView
20/20 Biolabs Inc. (AIDX) Slides 4.1% as Stock Tests Key Support at $0.47Large Cap Trends - dars.gov.et
20/20 Biolabs, Inc. (AIDX) stock price, news, quote and history - Yahoo Finance UK
Rokit Healthcare, US 20/20 BioLabs to Co-Develop AI Multi-Cancer Prediction Platform - Seoul Economic Daily
20/20 BioLabs enters standstill pact on preferred stock - Investing.com
20/20 BioLabs Enters Temporary Standstill Agreement Limiting Series E Preferred Stock Conversions - Quiver Quantitative
20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock - The Manila Times
Press Release: 20/20 BioLabs Announces Standstill Agreement With Streeterville Capital Regarding Series E Convertible Preferred Stock - Moomoo
20/20 Biolabs, Inc. Signs Standstill Agreement With Streeterville Capital – SEC 8-K Filing Details (July 2026) - Minichart
20/20 Biolabs Received Notice of Noncompliance - TradingView
20/20 Biolabs (Nasdaq: AIDX) signs standstill as Nasdaq flags bid-price issue - Stock Titan
Why Super Micro Computer Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Benzinga
What Factors Led to 20/20 Biolabs' Dramatic Stock Collapse - Kavout | AI
20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth - The Manila Times
20/20 BioLabs reports Q2 MCED revenue to be highest to date - Investing.com
20/20 BioLabs highlights OneTest™ strategy for Medicare coverage and reports strong Q2 revenue growth - Pluang
20/20 BioLabs Highlights Investor Webinar Focused on - GlobeNewswire
20/20 BioLabs targets Medicare path as Q2 revenue jumps 30% - scanx.trade
Virax Biolabs | 20-F: Registration statement / Annual report / Transition report - Moomoo
AIDX SEC Filings20/20 Biolabs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
20/20 Biolabs (AIDX) Jumps Nearly 5% as Stock Approaches Key $0.67 ResistanceIchimoku Cloud - dars.gov.et
20/20 Biolabs to present OneTest webinar outlining Medicare pathway, modeling and reimbursement plan - TradingView
OneTest growth vision: 20/20 Biolabs (AIDX) targets Medicare MCED market - Stock Titan
20/20 BioLabs’ Multi-Cancer Early Detection Test Now Available to Evexia Diagnostics' 40,000+ U.S. Practitioners - The National Law Review
20/20 Biolabs Inc. (AIDX) Edges Higher in Low-Price Territory as Support HoldsWyckoff Spring - dars.gov.et
20/20 Biolabs, Inc. Actuals & Estimates (NASDAQ:AIDX) - TradingView
Price to sales forward of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
Finanzdaten der 20 20 Biolabs Inc-Aktie (AIDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):